These Analysts Increase Their Forecasts On Immunovant After Q4 Results
Immunovant (NASDAQ:IMVT) reported a Q4 loss of 73 cents/share, missing estimates of 60 cents. R&D expenses rose to $142.3 million. Analysts adjust price targets.read more...
More News
IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data
Immunovant stock jumps 35% as strong early IMVT-1402 data in rheumatoid arthritis boosts confidence despite a wider Q4 loss.
IMVT Rockets 35% Despite Wider Loss As Arthritis Drug Shines In Study
Immunovant posted encouraging Phase 2 data for its rheumatoid arthritis therapy, even as fourth-quarter net loss came in wider than expected.
Can a New Arthritis Drug Make Immunovant the Next Biotech Star?
Can a New Arthritis Drug Make Immunovant the Next Biotech Star...
Clinical Catalysts Driving Momentum, Plus an Oldie and a Newie
Clinical catalysts are driving the market, this morning, plus a mover we’ve been covering for weeks and a new runner. $NTHI, $IMVT, $IBRX, $AMPG, $POET, $MWC
Immunovant, Inc. $IMVT Shares Sold by Pictet Asset Management Holding SA
Pictet Asset Management Holding SA lowered its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 43.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 380,842 shares of the company's stoc...
Immunovant, Inc. (NASDAQ:IMVT) Receives Average Recommendation of "Hold" from Analysts
Immunovant, Inc. (NASDAQ:IMVT - Get Free Report) has been assigned a consensus recommendation of "Hold" from the eleven research firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommenda...
Immunovant (NASDAQ:IMVT) Director Robert Graham Susman Sells 2,502 Shares
Immunovant, Inc. (NASDAQ:IMVT - Get Free Report) Director Robert Graham Susman sold 2,502 shares of the stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average...
Immunovant (NASDAQ:IMVT) CTO Sells $81,573.48 in Stock
Immunovant, Inc. (NASDAQ:IMVT - Get Free Report) CTO Jay Stout sold 2,754 shares of the business's stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $29.62...
Immunovant, Inc. (NASDAQ:IMVT - Get Free Report) CFO Tiago Girao sold 25,760 shares of the stock in a transaction dated Thursday, April 23rd. The shares were sold at an average price of $29.62, for a...